EcoDrugPlus

Fms Related Receptor Tyrosine Kinase 4

Ensembl ID : ENSCCRG00000044738
Gene Symbol: FLT4
1 Cross references
194 Possible Orthologues:

Folate Receptor Gamma

Ensembl ID : ENSCCRG00000022805
Gene Symbol: FOLR3
1 Cross references
436 Possible Orthologues:

Follicle Stimulating Hormone Receptor

Ensembl ID : ENSCCRG00000064180
Gene Symbol: FSHR
1 Cross references
200 Possible Orthologues:

Fyn Related Src Family Tyrosine Kinase

Ensembl ID : ENSCCRG00000045923
Gene Symbol: FRK
1 Cross references
214 Possible Orthologues:

Galactosidase, Alpha

Ensembl ID : ENSCCRG00000080520
Gene Symbol: GLA
1 Cross references
197 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSCCRG00000058382
Gene Symbol: GABBR2
1 Cross references
205 Possible Orthologues:

Gamma-Aminobutyric Acid (Gaba) B Receptor, 2

Ensembl ID : ENSCCRG00000078167
Gene Symbol: GABBR2
1 Cross references
205 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSCCRG00000038501
Gene Symbol: GABRA1
1 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha1

Ensembl ID : ENSCCRG00000053781
Gene Symbol: GABRA1
1 Cross references
201 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSCCRG00000013590
Gene Symbol: GABRA4
1 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha4

Ensembl ID : ENSCCRG00000053947
Gene Symbol: GABRA4
1 Cross references
198 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Alpha5

Ensembl ID : ENSCCRG00000077611
Gene Symbol: GABRA5
1 Cross references
263 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).